Tang, Wenshu
Zhou, Jingying http://orcid.org/0000-0002-9740-6159
Yang, Weiqin
Feng, Yu
Wu, Haoran
Mok, Myth T. S.
Zhang, Lingyun
Liang, Zhixian
Liu, Xiaoyu
Xiong, Zhewen
Zeng, Xuezhen
Wang, Jing
Lu, Jiahuan
Li, Jingqing
Sun, Hanyong
Tian, Xiaoyu
Yeung, Philip Chun
Hou, Yong
Lee, Heung Man
Lam, Candice C. H.
Leung, Howard H. W.
Chan, Anthony W. H.
To, Ka Fai http://orcid.org/0000-0003-4919-3707
Wong, John
Lai, Paul B. S.
Ng, Kelvin K. C. http://orcid.org/0000-0002-3679-6368
Wong, Simon K. H.
Wong, Vincent W. S.
Kong, Alice P. S. http://orcid.org/0000-0001-8927-6764
Sung, Joseph J. Y.
Cheng, Alfred S. L.
Funding for this research was provided by:
Research Grants Council, University Grants Committee (C4045-18W, 14105419, 14104820)
Li Ka Shing Foundation (Li Ka Shing Foundation)
Terry Fox Foundation (Terry Fox Foundation)
AstraZeneca (AstraZeneca Research Program (2017))
Article History
Received: 28 December 2021
Accepted: 14 April 2022
First Online: 20 May 2022
Competing interests
: JZ and ASLC received the funding support and drug (vistusertib) from AstraZeneca. VWSW has consultancy in 3V-BIO, AbbVie, Allergan, Boehringer Ingelheim, Center for Outcomes Research in Liver Diseases, Echosens, Gilead Sciences, Hanmi Pharmaceutical, Intercept, Inventiva, Merck, Novartis, Novo Nordisk, Perspectum Diagnostics, Pfizer, ProSciento, Sagimet Biosciences, TARGET PharmaSolutions and Terns; has lectures in Abbott, AbbVie, Bristol-Myers Squibb, Echosens, Gilead Sciences and Novo Nordisk; received research grants from Gilead Sciences; and holds stock as co-founder of Illuminatio Medical Technology Limited. The other authors declare no competing interests.